Categories: Business

Satsuma inventory crashes 80% as migraine remedy STS101 fails section 3 trial

[ad_1]

The Good Brigade

Satsuma Prescription drugs (NASDAQ:STSA) migraine remedy STS101 didn’t meet the primary objectives of a section 3 trial and the corporate stated it doesn’t plan to spend money on commercializing STS101 and can discover options to maximise worth and reduce money expenditures.

STS101 is a nasal powder formulation of anti-migraine drug dihydroergotamine mesylate (DHE) administered by way of Satsuma’s proprietary nasal supply machine,

The corporate stated knowledge from the research, dubbed SUMMIT, confirmed that STS101 was not statistically superior to placebo at two hours post-administration on the co-primary objectives of freedom from ache and most bothersome symptom (from amongst photophobia, phonophobia and nausea).

STS101 did, nevertheless, present superiority variations versus placebo on freedom from ache and most bothersome symptom in any respect timepoints after two hours post-administration (3, 4, 6, 12, 24 and 48 hours), and on a number of secondary objectives, together with ache reduction at 2 hours post-administration and all timepoints thereafter, the corporate added.

STS101 confirmed a good security and tolerability profile, in line with trial expertise so far, based on the corporate.

Satsuma stated that based mostly on earlier interactions with the FDA, it believes outcomes from the STS101 section 1 PK (pharmacokinetic) and ASCEND section 3 long-term, security trials will help NDA submitting and approval.

In September, Satsuma reported outcomes from ASCEND, which confirmed the therapy was protected, the primary aim of the trial.

“We’re shocked and upset that STS101 didn’t exhibit statistically important superiority over placebo at two-hours submit therapy on the SUMMIT research co-primary endpoints,” stated Satsuma’s President and CEO John Kollins.

Satsuma famous that it doesn’t plan to spend money on commercializing STS101.

As of Oct. 31, the corporate had estimated money and equivalents of $59.4M.

STSA -80.25% to $0.80 premarket Nov. 14

[ad_2]
Source link
admin

Recent Posts

Building a Future-Ready Electronic Company: Key Strategies for Success

In today's tech-driven world, electronic companies play a crucial role in shaping modern life, from…

2 days ago

Leading Strategies for Winning the Lotto

Hey there, fellow dreamers! Ever fantasized about hitting the jackpot and living the life of…

2 days ago

BOTTOM CAMP Unveils N Additionally Dust Mask

The Some Remarkable Plus woodworking dust masque combines advanced technology with design elements for a…

3 months ago

What Is a Reclaim Catcher?

Reclaim catchers speed up cleaning time for dab rigs by collecting residue that could build…

3 months ago

Choosing the Right Barn Exhaust Lovers

Barn exhaust fans provide airflow that reduces heating stress, makes livestock far healthier and happier,…

3 months ago

Precisely what Nutrients Should Your Dog Consume?

Your dog's health depends upon consuming a balanced diet, providing you with essential vitamins, minerals,…

3 months ago